Business Context and Reporting Period
Company: Supernus Pharmaceuticals, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: May 3, 2016
Reporting Period: First quarter ended March 31, 2016
Context: The filing announces the issuance of a press release regarding Q1 2016 financial results and schedules a conference call for May 4, 2016.
Key Financial Metrics
The provided text serves as a notification of results and does not contain specific financial data points. The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained in the attached Exhibit 99.1 (Press Release), which is referenced but not included in the input text.
Material Changes
No material changes or comparative financial data versus the prior period are detailed in this specific filing text. The document only confirms that results for the period ended March 31, 2016, have been issued.
Guidance, Outlook, and Risks
- Forward-Looking Statements: The filing contains forward-looking statements regarding plans, strategies, and intentions, identified by terms such as "believe," "expect," and "anticipate."
- Disclaimer: The company undertakes no obligation to update or revise these statements based on new information or future events.
- Risks: Forward-looking statements are subject to risks and uncertainties, including those detailed in Item 1A ("Risk Factors") of the Annual Report on Form 10-K for the fiscal year ended December 31, 2015.
- Legal Status: Information in Item 2.02 is "furnished" and not "filed" under Section 18 of the Exchange Act, limiting liability.
Investor Verification Checklist
- Review the attached Press Release (Exhibit 99.1) for specific Q1 2016 revenue and net loss figures.
- Verify the company's cash position and burn rate in the full press release or subsequent 10-Q filing.
- Check the Form 10-K filed on March 9, 2016, for detailed risk factors referenced in this 8-K.
- Confirm the outcome of the conference call held on May 4, 2016, for management commentary on the results.